International Niemann–Pick Disease Alliance
IMAGINE follows Millie, a little girl suffering from NP-C. Imagine has been developed in collaboration with the Hope for Hollie Foundation, NPUK and the INPDA, to raise awareness of the disease. We can’t wait to share it!
The transcript from Vtesse’s webinar, held on April 16th 2015, is available at the following link: http://www.vtessepharma.com/#!patient-webinars/c1nf6
Orphazyme’s ‘Observational’ study for NP-C has been registered and made available on www.clinicaltrials.gov. The trial identifier is NCT02435030. Confirmed sites and contact details are provided. https://clinicaltrials.gov/ct2/show/NCT02435030?term=arimoclomol&rank=5 You can find further information on Orphazyme’s website www.orphazyme.com
INPDA member Niemann-Pick UK provides a new post from Will Evans (father of Sam, NP-C, and trustee of NPUK), giving his perspective of the planned clinical trials in NP-C: New Post! Clinical Trials in NP-C – My Perspective, by...
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. This enzyme replacement therapy is being investigated for the treatment of patients with nonneurological manifestations of acid sphingomyelinase...
Ebola’s ‘Achilles heel’ has been identified by a team of scientists, prompting hopes of new treatments to stop the virus spreading. Researchers in New York believe they have located the vital protein, which affects whether or not the virus...
For six years, The Wall Street Journal followed a group of parents and scientists seeking a treatment for a rare and fatal genetic disease that strikes primarily children. Their collaboration accelerated development of a promising drug and, along the...
An article highlighting the INPDA’s campaign to improve diagnosis of NP-C is featured in today’s BBC News. Article can be viewed here: http://m.bbc.co.uk/news/health-31644877